CD160: A unique activating NK cell receptor

Bouteiller, Philippe Le; Tabiasco, Julie; Polgar, Beata; Kozma, Noémi; Giustiniani, Jérôme; Siewiera, Johan; Berrébi, Alain; Aguerre-Girr, Maryse; Bensussan, Armand; Jabrane‐Ferrat, Nabila

doi:10.1016/j.imlet.2011.02.003

Cited by 77 publications

(81 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…either stimulatory or inhibitory, depending on the cell type, the expression of the ligands (HVEM or MHC class I) [29]–[32] and the fact that CD160 exist in two isoforms (spliced variants) with and without transmembrane (TM) domain [33], [34]. In order to determine whether CD160/CD160-ligand interactions could negatively regulate CD8 T-cell signaling, virus-specific CD8 T-cell proliferation was assessed in the presence or in the absence of mAbs that block CD160/CD160-ligand signaling.…”

Section: Discussionmentioning

confidence: 99%

CD160-Associated CD8 T-Cell Functional Impairment Is Independent of PD-1 Expression

et al. 2014

View full text Add to dashboard Cite

Expression of co-inhibitory molecules is generally associated with T-cell dysfunction in chronic viral infections such as HIV or HCV. However, their relative contribution in the T-cell impairment remains unclear. In the present study, we have evaluated the impact of the expression of co-inhibitory molecules such as 2B4, PD-1 and CD160 on the functions of CD8 T-cells specific to influenza, EBV and CMV. We show that CD8 T-cell populations expressing CD160, but not PD-1, had reduced proliferation capacity and perforin expression, thus indicating that the functional impairment in CD160+ CD8 T cells may be independent of PD-1 expression. The blockade of CD160/CD160-ligand interaction restored CD8 T-cell proliferation capacity, and the extent of restoration directly correlated with the ex vivo proportion of CD160+ CD8 T cells suggesting that CD160 negatively regulates TCR-mediated signaling. Furthermore, CD160 expression was not up-regulated upon T-cell activation or proliferation as compared to PD-1. Taken together, these results provide evidence that CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression.

show abstract

Section: Discussionmentioning

confidence: 99%

CD160-Associated CD8 T-Cell Functional Impairment Is Independent of PD-1 Expression

et al. 2014

View full text Add to dashboard Cite

show abstract

“…19 its transcription activator (i.e., PF4 and USF1) and a natural killer receptor that recognizes MHC class Ia and Ib molecules (CD160) were among the top biomarkers for the vaccine nonresponder group. 36,37 It is worth noting that the majority of observations of transcriptional changes among the nonresponder group were indicative of downregulation of transcripts. Measureable biomarkers of disease state tend to be those transcripts which show positive transcription in order to measure changes; negative regulation is difficult to reliably demonstrate.…”

Section: Discussionmentioning

confidence: 99%

Host responses to live-attenuated Venezuelan equine encephalitis virus (TC-83)

Erwin-Cohen¹,

Porter²,

Pittman³

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Of note, while LAG-3 inhibits T cell responses, evidence exists that it might have an activating role in NK cells [84]. Similarly, it was shown that in NK cells CD160 could trigger cytotoxicity and secretion of IFN-γ, TNF-α, IL-6, IL-8 and MIP1-β [85], while having mainly inhibitory function in T cells [86]. Different roles of Tim-3 in the regulation of NK cell responses has been reported.…”

Section: Shaping Of Nk Cell Function By the Tumor Microenvironmentmentioning

confidence: 99%

Shaping of NK Cell Responses by the Tumor Microenvironment

Stojanović

Correia

Cerwenka

2012

Cancer Microenvironment

View full text Add to dashboard Cite

Natural killer (NK) cells belong to the innate immune system and are potent cytolytic and cytokineproducing effector cells in response to tumor targets. NK cell based anti-tumor immunotherapy was so far mainly successful in patients with different types of leukemia. For instance, acute myeloid leukemia (AML) patients displayed a prolonged survival if transplanted with haploidentical stem cells giving rise to NK cells with a mismatch in inhibitory killer immunoglobulin receptors (KIRs) and recipients' HLA class I. Although promising results have been achieved with hematological tumors, solid tumors are in most cases poorly controlled by NK cells. Therapeutic protocols that aimed at improving NK cell responses in patients with solid malignancies succeeded in increasing NK cell numbers and functional responses of NK cells isolated from the patients' peripheral blood. However, in the majority of cases tumor progression and overall survival of patients were not significantly improved. There is increasing evidence that tumor-associated NK cells become gradually impaired during tumor progression compared to NK cells from peripheral blood and healthy tissues. Future protocols of NK cell based immunotherapy should integrate three important aspects to improve NK cell anti-tumor activity: facilitating NK cell migration to the tumor site, enhancing their infiltration into the tumor tissue and ensuring subsequent efficient activation in the tumor. This review summarizes the current knowledge of tumor-infiltrating NK cells and the influence of the tumor microenvironment on their phenotype and function.

show abstract

CD160: A unique activating NK cell receptor

Cited by 77 publications

References 27 publications

CD160-Associated CD8 T-Cell Functional Impairment Is Independent of PD-1 Expression

CD160-Associated CD8 T-Cell Functional Impairment Is Independent of PD-1 Expression

Host responses to live-attenuated Venezuelan equine encephalitis virus (TC-83)

Shaping of NK Cell Responses by the Tumor Microenvironment

Contact Info

Product

Resources

About